Lupin`s Generic Canagliflozin, Metformin Hydrochloride Receives Approval in the U.S.
Ahmedabad: Zydus Lifesciences Limited, received tentative approval from the Unit ..
Zydus' Generic Canagliflozin, Metformin Hydrochloride Receives Approval in the U.S.
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Canagliflozin Tablets, 100 mg and 300 mg (USRLD: Invokana Tablets).
Laurus Labs' Generic Canagliflozin Receives Approval in the U.S.
DALLAS, Nov. 14, 2021 — Canagliflozin, a medication used to treat type 2ndiabetes, was found to greatly improve symptoms and quality of life nwithin 3 months for people with heart failure due to either reduced or npreserved cardiac function, even if they didn’t also have type 2 ndiabetes, according to late-breaking research presented today at the nAmerican Heart Association’s Scientific Sessions 2021.nThe meeting is fully virtual, Saturday, November 13-Monday, November n15, 2021, and is a premier global exchange of the latest scientific nadvancements, research and evidence-based clinical practice updates in ncardiovascular science for health care worldwide.
DALLAS, Nov. 14, 2021 — Adults treated with empagliflozin during hospitalization for acute heart failure experienced a clinical benefit such as increased survival, lower risk of heart failure hospital readmission and an overall improvement in their quality of life, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2021. The meeting is fully virtual, Saturday, November 13-Monday, November 15, 2021, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.
In the last year, two SGLT2 inhibitors — initially developed to treat diabetes — have snagged approvals in the heart failure space. Now Johnson & Johnson is jumping on the bandwagon, reading out positive Phase III results for its own SGLT2 drug Invokana.
NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic response and improvements in kidney health over time in adults with type 2 diabetes. By accurately assessing therapeutic response, particularly in patients at high risk for kidney failure, KidneyIntelX can potentially address a major barrier for primary care physicians and specialists in using new pharmaceuticals to slow kidney disease and improve outcomes. The data from an international study of 1,100 individuals with diabetic kidney disease (DKD) in the CANagliflozin Cardiovascular Assessment Study (CANVAS), was presented at the American Diabetes Association 81st Scientific Sessions Virtual Meeting (June 25-29, 2021).